# Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

> **NCT00633464** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 79 (actual)

## Conditions studied

- Triple Negative Locally Advanced Non-resectable Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** ixabepilone
- **DRUG:** ixabepilone + cetuximab

## Key facts

- **NCT ID:** NCT00633464
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-09
- **Final completion:** 2011-05
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633464, "Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00633464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*